A qualitative evaluation of the process of creating and implementing an interprofessional care pathway for patients treated with oral anticancer drugs.

Eur J Oncol Nurs

Department of Public Health and Primary Care, University Centre for Nursing and Midwifery, Ghent University, Corneel Heymanslaan 10, 5K3 Entrance 42, 5th floor, 9000, Gent, Belgium; Department of Nursing, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Gent, Belgium. Electronic address:

Published: December 2022

Purpose: To investigate factors affecting the co-creation and implementation of care pathways for patients treated with oral anticancer drugs.

Methods: An explorative qualitative process evaluation was performed at four Belgian hospitals, co-creating and implementing a care pathway for patients on oral anticancer drugs. Semistructured interviews and focus groups were performed by a) local coordinators leading an interprofessional project team during the co-creation and implementation stage, b) external implementation coaches, and c) teams of healthcare professionals with a role in the care pathway. In total, 47 stakeholders were interviewed. Interviews were audio-taped, transcribed verbatim, and analyzed thematically.

Results: We found four factors affecting co-creation and implementation of care pathways for patients on oral anticancer drugs. Developing an adequate supporting context using motivated interprofessional project teams of clinical and management staff led by competent coordinators is one important facilitator. Leadership of local coordinators and oncologists is crucial for progressing the co-creation. Other factors included the complexity of the oral anticancer drug intervention, the interprofessional character of the care pathway, and involving primary care. External coaching during co-creation proved an important facilitator.

Conclusions: Prior investigation of willingness and motivation to change in clinical and management staff, competent coordinators, and leadership of oncologists are needed. In addition, external support determines the success of co-creating and implementing care pathways for patients on oral anticancer drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejon.2022.102218DOI Listing

Publication Analysis

Top Keywords

oral anticancer
24
care pathway
16
anticancer drugs
16
co-creation implementation
12
care pathways
12
pathways patients
12
patients oral
12
care
8
pathway patients
8
patients treated
8

Similar Publications

Autophagy-targeted Pt(IV) agents: a new horizon in antitumor drug development.

Dalton Trans

January 2025

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, P. R. China.

Pt(IV) complexes as prodrugs of Pt(II) drugs exhibit numerous advantages such as enhanced stability, reduced toxicity, increased oral bioavailability, and efficacy in overcoming the drug resistance of Pt(II) compounds, which underscore their significant potential in the advancement of novel Pt anticancer agents. Furthermore, protective autophagy is pivotal in sustaining tumor cell homeostasis and modulating the tumor microenvironment (TME), thereby representing a critical target for the development of antitumor drugs. Specific inhibition or activation of autophagy during chemotherapy would break the internal homeostasis in the TME and increase antitumor activities.

View Article and Find Full Text PDF

Geraniol is an acyclic monoterpene alcohol that is extracted from the essential oils of aromatic plants. Geraniol has several biological activities such as anti-cancer, anti-inflammatory, antioxidant, and neuroprotective effects. However, the pharmacokinetics of geraniol and its metabolites after oral administration remain unknown in mice.

View Article and Find Full Text PDF

Imidazo based heterocyclic derivatives are considered as privileged scaffolds due to their presence in various pharmacologically active compounds and in marketed formulations. The present study reports toxicological evaluation of three imidazo based heterocyclic derivatives which are currently being investigated for their potential anticancer activity. Compounds IG-01-007, IG-01-008, and IG-01-009 were assessed for cytotoxicity, hemolysis, and DNA fragmentation activity.

View Article and Find Full Text PDF

Repurposing bosentan as an anticancer agent: EGFR/ERK/c-Jun modulation inhibits NSCLC tumor growth.

Fundam Clin Pharmacol

February 2025

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt.

Drug repurposing of well-established drugs to be targeted against lung cancer has been a promising strategy. Bosentan is an endothelin 1 (ET-1) blocker widely used in pulmonary hypertension. The current experiment intends to inspect the anticancer and antiangiogenic mechanism of bosentan targeting epidermal growth factor receptor (EGFR) /extra-cellular Signal Regulated Kinase (ERK) /c-Jun/vascular endothelial growth factor (VEGF) carcinogenic pathway.

View Article and Find Full Text PDF

The synergistic bioactive effect of polyphenols can enhance the development of functional foods to prevent chronic diseases such as cancer. Curcumin and quercetin have been shown to possess anticancer properties. The combination of curcumin and quercetin has been shown to provide synergistic effects against cancer cell proliferation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!